Girl-Woman-Beauty-Brains-Blog

We don't care if SATC star Cynthia Nixon had cosmetic surgery; We just want to set the record straight on this senseless and groundless tittle-tattle about the 42-year-old celeb allegedly undergoing a boob job.

Feisty Cynthia -- you go, girlfriend -- "delivered a swift kick in the ovaries" to the truth-challenged New York Post, who reported last week that she had a boob job. She admits she consulted with doctors about her breasts -- specifically, for her breast cancer check-up.

Why do we want to set the record straight? Sometimes gossip is a good thing. This gossip is our reminder to do a BSE - breast self exam - and have a mammogram every one to two years starting at age 40.

Cynthia added:

"I was at St. Luke's-Roosevelt Hospital for my 'three-monthly' checkup," said Nixon, a breast-cancer survivor. "I was in the Oncology Department. I guess they think that means 'plastic surgery.'"

Related articles:

Beauty and Beast - Breast Cancer
8 Ways to Deal with Toxic Chemicals in Beauty Products

Sources:
BreastCancer.org
WittySparks.com
National Post

We have not written a post recently about beautynomics, primarily because who wants to write about all that doom and gloom, but according to financial-istas (hot off the presses), it looks like Allergan --makers of Lumilash, Botox, Juvederm, Botox, and breast implants -- could have a good return on your investment. So you may want to add this to your stock portfolio investments, as well as your beauty portfolio.

According to Bernstein Research,

• 
  
• The most important development presented yesterday was the unveiling of the Lumilash program. Lumilash makes eyelashes longer, darker and fuller and has minimal side-effects (it did not, as we feared, cause a change in eye color). We expect strong uptake and peak sales approaching $500M. (Girl-Woman will be one of the first bloggers to be testing and reviewing Lumilash.)
• 
  
• The other key development was the announcement AGN is pushing forward the Juvederm with Lidocaine program where it now expects approval by YE09. This is a next generation dermal filler that could help AGN break the tie with MRX's Restylane – a largely equivalent product. Between Lumilash, Juvederm w/ Lidocaine and the Clinique products, Allergan is building a lead over other aesthetic companies, notably MRX -- Medicis Pharmaceutical Corp. It is difficult to see aesthetic physicians being unhappy with AGN given the assortment of new products. (See Girl-Woman's comparison of Restylane and Juvederm). Additionally, according to my derm's office, there is a new kid on the block -- Radiesse. Radiesse is one of the longest-lasting dermal fillers available. Once it is injected, it actually stimulates the production of collagen. Girl-Woman will test Radiesse in the future and compare it to Juvederm and Restylane.
• There is also solid mid term progress which may come to fruition around 2010. The FDA may consider reducing the number of cycles required in the Botox-OAB clinical trials. There were also no delays in follow on Lap-Band programs in adolescence and lower BMI patients.

Read More......